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Key Points
• Patients with relapsed or
refractory transformed indolent
lymphoma and DLBCL have
similar outcomes with salvage
therapy and ASCT.
• This therapy should be
considered the standard of
care for previously treated
transformed indolent
lymphoma.
The treatment of transformed indolent lymphoma (TRIL) often includes salvage chemo-
therapy (SC)andautologousstemcell transplant (ASCT).NCICCTGLY12 isa randomized
phase 3 trial comparing gemcitabine, dexamethasone, and cisplatin (GDP) with dexa-
methasone, cytarabine, and cisplatin (DHAP) before ASCT. This analysis compares the
results of SCandASCT for TRILwithdenovodiffuse largeB-cell lymphoma (DLBCL). Six-
hundred nineteen patients with relapsed/refractory aggressive non-Hodgkin lymphoma
were randomized to GDP or DHAP; 87 patients (14%) had TRIL and 429 (69%) had DLBCL.
The response rate to SC was 47% in TRIL and 45% in DL (P5 .81). Transplantation rates
were similar: TRIL 53%andDL52% (P5 1.0).With amedian follow-upof 53months, 4 year
overall survivalwas39% for TRILand41% forDL (P5 .78); 4 year event-freesurvival (EFS)
was 27% for TRIL and 27% for DL (P5 .83). Post-ASCT, 4-year EFS was 45% for TRIL and
46% for DL. Histology (TRIL or DL) was not a predictor of any outcome in multivariate
models. Patientswith relapsed or refractory TRIL andDLBCLhave similar outcomeswith
SC and ASCT; this therapy should be considered the standard of care for patients with
TRIL who have received prior systemic chemotherapy. NCIC CTG LY12 is registered at ClinicalTrials.gov as #NCT00078949. (Blood.
2015;126(6):733-738)
Introduction
Histologic transformation in patients with indolent non-Hodgkin
lymphoma (iNHL) involves the development of an aggressive his-
tology lymphoma after a prior diagnosis of iNHL. In follicular lym-
phoma, the risk of transformation has been estimated to be ;2% to
3% per year from the initial diagnosis, leading to a cumulative risk of
25% to 30% at 10 years.1-3 Historical cohort data in patients with
transformed indolent lymphoma (TRIL) have typically reported
poor overall survival (OS) despite combination chemotherapy, with
most patients dying from progressive disease.1-5
Treatment of transformed indolent lymphoma has been variable
and generally described in retrospective patient cohorts. Given the
perception of poor outcomewith standard-dose chemotherapy, selected
patients (typically younger and without prohibitive comorbidities)
are treated with aggressive strategies involving autologous stem cell
transplantation (ASCT) or allogeneic stem cell transplantation.6-16
A retrospective case-control comparison of outcomes of ASCT in
patients with TRIL or with de novo intermediate or high-grade
lymphoma published more than 10 years ago by the European
Society for Blood and Marrow Transplantation (EBMT) suggested
similar outcomes in these groups.14WithASCTdeﬁned as a standard
therapy for relapsed diffuse large B-cell lymphoma (DLBCL) and
other aggressive histology NHL based on the randomized Parma
trial,17 the EBMT review concluded thatASCT should be considered
for TRIL.
Reports of transplant outcomes for TRIL are limited by the
retrospective nature of the majority of these reports and the inherent
selection bias of solely reporting transplanted patients. The propor-
tion of patients able to respond to aggressive salvage chemotherapy,
mobilize peripheral blood stem cells (PBSCs), and undergo subse-
quent transplantation has not been well deﬁned or reported in
prospective studies. This analysis was designed to help address the
lack of prospective data in this area.
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The NCIC Clinical Trials Group (NCIC CTG) LY.12 study was a
randomized controlled trial designed to compare gemcitabine, dexa-
methasone, and cisplatin (GDP) with dexamethasone, cytarabine, and
cisplatin (DHAP) as salvage chemotherapy before autologous trans-
plantation (ﬁrst randomization), and to evaluate the efﬁcacy of post-
transplantation treatment with the anti-CD20 antibody rituximab
(second randomization). The results of the ﬁrst randomization demon-
strated thatGDPwasnoninferior toDHAP in termsof response rate and
resulted in a similar percentage of patients proceeding to ASCT, with
signiﬁcantly less toxicity and need for hospitalization.18 Here, we
present the outcome of a planned subset analysis of patients with TRIL
enrolled onto this study compared with patients with de novo DLBCL.
Methods
The NCIC Clinical Trials Group LY.12 study was an international randomized
controlled trial conducted in 26 Canadian and 10 American centers, and 1
Australian center, and, in collaboration with the Gruppo Italiano Studio Linfomi
(GISL), 18 centers in Italy. Details of the trial design, conduct, and ﬁnancial
support are reported elsewhere.18 The trial was approved by the research ethics
boards of all participating centers, andwritten informed consentwas provided by
all participants.
Patient selection for this subset analysis
From the entire LY12 cohort, we identiﬁed patients with biopsy-proven indolent
B-cell NHL and simultaneous or subsequent histologic evidence of transforma-
tion to aggressive histology B-cell lymphoma for inclusion in this preplanned
subset analysis. The following preceding indolent lymphomas were included:
follicular lymphomagrade 1-3A,marginal-zone lymphoma, lymphoplasmacytic
lymphoma, and small lymphocytic lymphoma/chronic lymphocytic leukemia.
The following aggressive transformation histologies were included: DLBCL,
Burkitt lymphoma, B-cell NHLwith features intermediate betweenDLBCL and
Burkitt lymphoma, and lymphoblastic lymphoma.19 Pathology was reviewed at
each center by a local reference pathologist at the time of TRIL diagnosis or
treatment and pathology reports both at the time of initial diagnosis and subse-
quent transformation were reviewed by a physician at the operations ofﬁce of
NCIC CTG.
Patients with TRIL were eligible for randomization if they had received no
more than three prior systemic treatments (before an amendment early in the trial,
therewasno limit toprior systemic therapy).Baselineassessments includedphys-
ical examination; standard laboratory testing; computed tomography (CT)
scanning of the chest, abdomen, and pelvis; bone marrow biopsy; and, if
indicated, cerebrospinal ﬂuid analysis. Eligible patients were required to have
measurable disease by CT scan or physical examination, an Eastern Coop-
erative Oncology Group Performance Status of 0-3,20 and acceptable
hematologic and biochemical parameters. Patients were excluded if they
previously received treatment with cisplatin, cytarabine, or gemcitabine, had
central nervous system involvement with lymphoma, a history of HIV infec-
tion, or amedical condition that would interfere with safe delivery of protocol
chemotherapy.
At the time of randomization, eligible patientswere stratiﬁed by International
Prognostic Index at trial entry,21 response to primary therapy, immunophenotype
(B vs T cell), study center, and prior rituximab exposure. Centers were permitted
to use local practices and policies for stem-cell mobilization and transplantation
and supportive care.
Response assessment
The primary outcome for the ﬁrst randomization of LY12 was response
(complete, unconﬁrmed complete, or partial response) after 2 cycles of therapy,
according to InternationalWorkshopCriteria22; ﬂuorodeoxyglucose positron
emission tomography was not used to assess response. OS was calculated from
the date of randomization to the date of death from any cause; event-free survival
(EFS) was calculated from the date of randomization to the date of disease
progression, relapse after objective response, initiation of new lymphoma ther-
apy, or death from any cause. Response rate, EFS, and OSwere evaluated using
data froman intention-to-treat population.Adverse eventsweregradedaccording
to National Cancer Institute Common Toxicity Criteria Version 2.0.22
Statistical analysis
The primary analysis of LY12 met its noninferiority end point; there was no
signiﬁcant association between study arm (GDP vs DHAP) and the primary end
point of response, or the secondary end points of EFS or OS. Patients with TRIL
or DLBCL receiving either GDP or DHAP were combined for this secondary
analysis. Thex2 test23was used to compare the rates of response, transplantation,
adverse events, and successful stem cell mobilization between patients with
TRIL and de novo DLBCL. The life-table method of Kaplan and Meier24 was
used to calculate EFS and OS, and groups were compared using the log-rank
test.25 All analyses were performed using SAS software, version 9.2 (SAS
Institute Inc., Cary, NC).
Results
Patient characteristics
During the period from August 2003 to November 2011, 619 patients
were randomized in LY.12. Eighty-seven patients had TRIL at the time
of study enrollment (43 patients randomized to GDP and 44 to DHAP)
and 428 patients were enrolled with DLBCL (220 randomized to GDP
and 209 to DHAP; Table 1). The remainder had lymphomas of T or
natural killer cell origin. The indolent histology in the TRIL group was
follicular lymphoma in78patients (90%)andmarginal zone lymphoma
in 4 (5%), with the other cases including unclassiﬁed and lympho-
plasmacytic lymphoma (n55). In patientswith an indolent lymphoma,
the time to diagnosis of DLBCL ranged from 0 to 205 months, with
a median of 29 months. The median age was 56 in both the TRIL and





Response to primary treatment
,1 y 41 (47) 180 (42)
.1 y 23 (26) 116 (27)
Refractory to primary treatment, SD PD 23 (26) 133 (31)
Age (y), median (range) 56 (31-69) 55.5 (19-74)
.60 26 (30) 130 (30)
Bone marrow involvement, yes 35 (40) 23 (5)
ECOG PS
0-1 74 (85) 375 (87)
$2 13 (15) 54 (13)
Disease stage
I-II 18 (21) 144 (34)
III-IV 69 (79) 285 (66)
Number of prior systemic therapies
1 52 (60) 429 (100)
2 21 (24) 0
$3 14 (16) 0
Prior radiation 31 (36) 97 (23)
Prior rituximab 59 (68) 325 (76)
Elevated LDH 35 (40) 188 (44)
B symptoms 20 (23) 153 (36)
Extranodal sites
0-1 66 (76) 318 (74)
$2 21 (24) 111 (26)
Values are n (%). LDH values were missing in 1 (1.1%) TRIL patient and in 5 (1.2%)
DLBCL patients. The presence or absence of B symptoms was not recorded in 4 (4.5%)
TRIL patients and 15 (3.5%) DLBCL patients. PD, progressive disease; SD, stable disease.
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DLBCLgroups, with 30% of patients in both groups over the age of 60
years. Bone marrow involvement was documented in 35 of the TRIL
patients; a small-cell lymphoma was noted in 13, large cell in 15, both
small and large cell in 4, andmorphologywas unavailable in 3 patients.
All patients with DLBCL had 1 prior systemic therapy (n 5 429);
patients with TRIL had 1 (n5 52), 2 (n5 21), or 3 or more (n5 14)
prior lines of systemic therapy. Prior therapy included rituximab in 68%
of TRIL patients and 76% of DLBCL patients, with 36% of the TRIL
patients and 23% of the DLBCL patients having received prior
radiation. The proportion of patients with primary refractory disease
(no response or progressive disease to anthracycline-based treatment)
and early relapse (CR rate of,1 year) to last prior therapy was similar
within the 2 groups (Table 1). Of the 87 TRIL patients, 43 received
GDP and 44 receivedDHAP,whereas of the 429DLBCLpatients, 220
and 209 received GDP and DHAP, respectively.
Response rate, transplantation rate, and stem cell mobilization
and maintenance
The response rate to salvage chemotherapy in TRIL patients was
47% and was also 45% in DLBCL patients (P 5 .81). Response
rates appeared similar in patients receivingGDP or DHAP but were
not statistically compared. The percentage of patients proceeding
to ASCT (transplantation rate) was 52% in DLBCL and 53% in
TRIL groups (P 5 1.0). Successful PBSC mobilization (deﬁned
as $2 3 106 CD341 cells/kg) was achieved in 84% of TRIL and
87% of DLBCL patients (Table 2).
Outcomes after chemotherapy and ASCT
With a median follow-up of 53 months from the time of ﬁrst random-
ization, the 4-year OSwas 39% for TRIL patients and 41% forDLBCL
patients (P 5 .78; Figure 1A). Four-year EFS was 27% for TRIL pa-
tients and 27% for DLBCL patients (P 5 .83; Figure 1B). Among
patients who underwent ASCT, the 4-year OS was 65% for TRIL and
63% for DLBCL (P5 .91; Figure 2A), whereas the EFSwas 45% and
46%, respectively (P5 .78; Figure 2B).
In total, 218 of the 516 patients were randomized to maintenance
rituximab or observation. In the TRIL group, 16 received maintenance
therapy and 22 were observed, whereas in the DLBCL group, 95
received rituximab and 85 were observed.
Adverse events during salvage therapy
Patients were evaluated using NCI Common Toxicity Criteria version
2.0. The rate of febrile neutropenia was 18% in the TRIL patients (11%
in the GDP arm and 26% in the DHAP arm) and was 26% in the
DLBCL patients (18% in the GDP arm and 35% in the DHAP arm).
Hospitalizations for adverse events or illness occurred in 36% of TRIL
patients (33% GDP, 40% DHAP) and 33% of DLBCL patients (25%
GDP, 41% DHAP).
Prognostic factors and multivariate analysis
A multivariate Cox model was constructed to look at predictors of
response, successful PBSC mobilization, transplantation rate, and OS
and EFS. The multivariate results for OS and EFS are summarized in
Table 3. Histology (TRIL or DLBCL) was not a predictor of any of
these outcomes. Statistically signiﬁcant adverse prognostic factors for
ORR (data not presented), OS, and EFS were: refractory disease after
primary therapy before study enrollment, lack of complete response/
partial response to salvage therapy, and prior rituximab exposure. Ad-
ditional signiﬁcant adverse prognostic factors for OS and EFSwere the
presence of B symptoms or elevated lactate dehydrogenase (LDH).
Discussion
Although previous reports of patients with TRIL reported poor out-
comes,10 more recent reports have suggested that survival may be
improving: Recent data from the Iowa/Mayo SPORE described a
median survival of 50 months post-transformation in their series.26 A
series from the US National Comprehensive Cancer Network reported
similar favorable outcomes with earlier follow-up.10 These improve-
ments may be explained by earlier identiﬁcation of transformed lym-
phoma and also by the impact of treatments such as rituximab-based
chemotherapy and stemcell transplantation. Prospective or larger series
of transplant-based strategies have not been reported until recently.13,15
Similarly, there have been limited data reporting the outcome of the
denominator of patients being treated with a goal of ASCT despite the
recognition that a signiﬁcant proportion of patients will not undergo
transplantation.11,16
This planned subset analysis of prospectively collected NCIC CTG
LY.12 data represents the largest comparison of response to salvage
therapy and outcomes post-ASCT for patients with transformed vs de





(N 5 429) P
ORR
GDP (N: 43 1 220 5 263) 19 (44) 103 (47)
DHAP (N: 44 1 209 5 253) 22 (50) 92 (44)
Total 41 (47) 195 (45) .81
ASCT rate
GDP 21 (49) 118 (54)
DHAP 25 (57) 106 (51)
Total 46 (53) 224 (52) 1.0
PBSC mobilization success 41/49 (84) 220/252 (87)
Values are n (%) unless otherwise noted.
ORR, overall response rate.
Table 3. Multivariate analyses for overall survival and event-free
survival from time of randomization
OS EFS
Variable HR (95% CI) P HR (95% CI) P
Treatment arm—GDP 1.05 (0.82-1.34) .67 1.02 (0.82-1.27) .84
Histology—TRIL 0.92 (0.66-1.27) .61 0.83 (0.62-1.13) .23
Duration of CR/PR
,1 y vs SD/PD for
previous therapy
0.68 (0.52-0.88) .004 0.68 (0.53-0.87) .002
Duration of CR/PR
.1 y vs SD/PD for
previous therapy
0.24 (0.16-0.37) ,.0001 0.31 (0.22-0.44) ,.0001
Age .60 y 1.15 (0.88-1.50) .30 1.14 (0.90-1.44) .27
BM involved 0.99 (0.61-1.63) .99 1.13 (0.74-1.75) .57
ECOG PS 0-1 0.98 (0.69-1.38) .89 1.08 (0.78-1.49) .66
Stage I-II 0.95 (0.71-1.27) .72 0.84 (0.65-1.09 .19
Prior radiation 1.31 (0.98-1.76) .07 1.25 (0.95-1.64) .11
Prior rituximab 1.59 (1.14-2.24) .007 1.66 (1.24-2.22) .0007
Normal LDH 0.40 (0.31-0.53) ,.0001 0.52 (0.41-0.66) ,.0001
Presence of B
symptoms
1.47 (1.14-1.89) .003 1.32 (1.05-1.66) .02
Extranodal sites 0-1 0.65 (0.49-0.87) .003 0.79 (0.61-1.02) .08
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novo DLBCL reported to date. Both patient groups were uniformly
treated and evaluated, removing the selection bias inherent in cohort
descriptions of single-institution series or those from transplant
registries. Patients with TRILwhomet eligibility criteria for LY.12 had
a similar complete and overall response rate to salvage chemotherapy,
and a similar likelihood of proceeding to ASCT as did those with
DLBCL in the ﬁrst relapse or progression. Although the follow-up is
relatively short at 53 months for the entire cohort, 4-year OS and EFS
were similar for the 2 groups. The aim of this analysis was to report the
outcomes of relapsed/refractory TRIL using a clearly established stan-
dard of care for relapsed or refractory DLBCL (salvage chemotherapy
andASCT) to determinewhether this treatment achieves similar results
in TRIL.
Multivariate analysis of the population included in this analysis
identiﬁed prior rituximab treatment, response to primary or salvage
chemotherapy, elevated LDH, and B symptoms as being indepen-
dent predictors of EFS; these 4 variables and the presence ofmultiple
extranodal sites were also predictive of OS. Treatment arm (GDP or
DHAP) and histology (TRIL or DLBCL) were not independently
prognostic for EFS or OS.
The ﬁnding of prior rituximab-based therapy as an independent
predictive factor in this analysis is similar to the results of the Coral
trial in relapsed or refractory DLBCL and highlights the challenges of
treating patients after they have progressive lymphoma after rituximab-
based therapy.27 In relapsed and refractory DLBCL, the HOVON-44
trial reported improved response to salvage therapy and EFS with the
additionof rituximab, comparedwith chemotherapyalone, but the large
majority of patients in that trial had not been previously exposed to
rituximab during primary therapy.28 The value of rituximab-based
therapy for TRIL has been suggested in several available series, but the
importance of including rituximab-retreatment during salvage therapy
for TRIL before ASCT is not known.10,16,26
In the second randomization of LY12, patients with CD201 lym-
phoma who had recovered from ASCT were assigned to rituximab
375 mg/m2 every 2 months for 6 doses, or observation.. Rituximab
maintenance therapy after ASCT for follicular lymphoma has been
recently reported to improve progression-free survival (PFS) but has
not been evaluated prospectively inTRIL.29 It is possible that rituximab
maintenancemay be contributing to the favorable post-ASCT outcome
Figure 2. Overall survival and event-free survival from date of ASCT. (A) OS
from date of ASCT. With a median follow-up of 53 months, the 4-year OS post-ASCT
was 65% for the TRIL cohort (blue line) and 63% for the DLBCL cohort (red line)
(P 5 .61). (B) EFS from date of ASCT. With a median follow-up of 53 months, the
4-year EFS was 45% for the TRIL cohort (blue line) and 46% for the DLBCL cohort
(red line) (P 5 .97).
Figure 1. Overall survival and event-free survival from randomization. (A)
Overall survival (OS) from randomization. With a median follow-up of 53 months, the
4-year OS was 48% for the TRIL cohort (blue line) and 51% for the DLBCL cohort
(red line) (P5 .61). (B) Event-free survival (EFS) from randomization. With a median
follow-up of 53 months, the 4-year EFS was 26% for the TRIL cohort (blue line) and
27% for the DLBCL cohort (red line) (P 5 .61).
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of the TRIL cohort, but the small number of patients in this cohort may
limit the interpretation of these data. The outcome data from the second
randomization will be reported in a separate manuscript.
The total sample size of theNCICCTG.LY12cohort provided80%
power to detect clinically meaningful differences in overall response
rate to salvage chemotherapy of 17% or higher (2-sided a5 .05), but
differences in this efﬁcacy end point were not evident between
the TRIL and DLBCL cohorts. Similarly, important adverse events
such as febrile neutropenia and hospitalization for management of
toxicity were also not statistically different. Given the potential for
further additional chemotherapy exposure in the TRIL cohort as a
result of the underlying indolent lymphoma, it is important to note that
the efﬁcacy in the TRIL patients was not associated with excessive
toxicity. Although significant differences in efﬁcacy or toxicity were
not noted in this analysis of.500patients, it remains a limitationof this
dataset that the trial was not designed to study differences between
these histologic subtypes.
In addition, biopsy at the time of relapse post-transplant was not
mandated in the study protocol; therefore, it is not known in the patients
with TRIL whether relapse was caused by the aggressive or indolent
component of their disease. Transformation to DLBCL from an indo-
lent lymphoma is accompanied by a complex series of molecular
events,30,31 and biopsy of patients with TRIL at time of progression post-
ASCTrepresentsanopportunity to furtherunderstand thepotential roleof,
for example, novel targeted therapies in thepre- andposttransplant setting.
Although there are few series that have reported the outcomes
of patients with TRIL undergoing salvage chemotherapy and
ASCT, our results compare favorably with these smaller and
typically retrospective series. The major limitations of this
analysis include the relatively modest sample size of 89 patients
and lack of uniform exposure to rituximab in the TRIL cohort.
Unfortunately, the other available series do not address these
issues optimally. A prospective study from Norway evaluating
chemotherapy and ASCT reported the outcome of 47 patients in
which chemo-sensitive patients would undergo ASCT.11 The
response rate to chemotherapy pre-transplant was 72%, and 64%
of patients underwent ASCT. For the entire cohort, the 5-year OS
was 43% and for the transplanted patients, the 5-year OS and PFS
post-ASCT were 47% and 32%, respectively. Many of the
patients were accrued to this trial before the availability of
rituximab for treatment of both the indolent or transformed ag-
gressive histology, and this trial did not complete full accrual.
Investigators at thePrincessMargaretHospital reported retrospective
results of a cohort of TRIL patients treated with salvage chemotherapy
and ASCT between1996 and 2009.16 One-hundred ﬁve patients with
TRIL underwent chemotherapy with cyclophosphamide, hydroxydau-
norubicin, oncovin, prednisone (18%), a variety of platinum-containing
regimens (63%), or rituximab-based therapy (27%).The response rate to
chemotherapy was 57%, with 48% of all patients proceeding to ASCT.
Three-year OS and PFS post-ASCT were 54% and 42%, respectively.
Patients transplanted after 2004 or who received rituximab-based
therapy immediately before ASCT had improved OS.
Many questions in the management of TRIL remain unan-
swered. However, we believe our analysis provides clarity in the
management of patients with relapsed or refractory TRIL. The
response to salvage chemotherapy, the ability to collect peripheral
blood stem cells, and EFS and OS for patients with TRIL are
similar to those for de novo DLBCL and support the use of salvage
chemotherapy and ASCT as the standard of care for this patient
population.
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